
La Food and Drug Administration (FDA) approuve la commercialisation de l’AMX0035 (Amylyx) pour le marché américain
Au cours de la réunion de la commission consultative sur les médicaments…

Measuring treatment effects based on patient preference
To evaluate the effect of an investigational drug in ALS clinical trials,…

TRICALS Enrols First Participants in Phase 3 MAGNET platform trial for ALS
TRICALS (the Treatment Research Initiative to Cure ALS), in collaboration with ALS…

USA: new law promises $100 million for ALS research
A new law has been passed in the United States to give…

Congratulations to our TRICALS colleagues as UK Government invests £50 million to find a cure for ALS
The UK government has recently announced that £50 million will be invested…

A road map for digital health care technology in MND
The COVID-19 pandemic has had an important impact on the development and…

Amylyx Pharmaceuticals and TRICALS to collaborate on phase 3 clinical trial
Today, Amylyx Pharmaceuticals provided an update on its plans to advance its…

Newsletter December 2020
2020 has been a difficult year for everyone. However, despite the many…